$ENGN 4 SEC Filings

Filed On	Filing
24 Sep 2026	Form 4: Grossman William, Director Bought 5,102 shares ($10.1K)
17 Jun 2026	Form 4: Astley-Sparke Philip, Director Granted 31,000 Stock Option (Right to Buy)
17 Jun 2026	Form 4: Brunk Gerald A, Director Granted 31,000 Stock Option (Right to Buy)
17 Jun 2026	Form 4: Glickman Richard M, Director Granted 31,000 Stock Option (Right to Buy)
17 Jun 2026	Form 4: Grossman William, Director Granted 231,000 Stock Option (Right to Buy)
17 Jun 2026	Form 4: Hastings Paul J, Director Granted 31,000 Stock Option (Right to Buy)
17 Jun 2026	Form 4: Heffernan Michael Thomas, Director Granted 31,000 Stock Option (Right to Buy)
17 Jun 2026	Form 4: Joustra Wouter, Director Granted 31,000 Stock Option (Right to Buy)
17 Jun 2026	Form 4: Zoth Lota S., Director Granted 31,000 Stock Option (Right to Buy)
03 Feb 2026	Form 4: Cheung Anthony Tzeyew, Chief Scientific Officer Granted 195,000 Stock Option (Right to Buy)
03 Feb 2026	Form 4: Giguere Lee, Chief Legal Ofc. and Corp Secy Granted 195,000 Stock Option (Right to Buy)
03 Feb 2026	Form 4: Nichols Alexander Julian, Chief Strategy & Ops. Ofc Granted 195,000 Stock Option (Right to Buy)
03 Feb 2026	Form 4: Daws D. Ryan, Chief Financial Officer Granted 220,000 Stock Option (Right to Buy)
03 Feb 2026	Form 4: Cooper Ronald Harold Wilfred, Director Granted 801,000 Stock Option (Right to Buy)
03 Feb 2026	Form 4: Connolly Joan, Chief Technology Officer Granted 195,000 Stock Option (Right to Buy)
03 Feb 2026	Form 4: Boyd Matthew Ross, Chief Regulatory Officer Granted 195,000 Stock Option (Right to Buy)
03 Feb 2026	Form 4: Buck Jill, Chief Development Officer Granted 195,000 Stock Option (Right to Buy)
01 Oct 2025	Form 4: Sweiti Hussein, Chief Medical Officer Granted 600,000 Stock Option (Right to Buy)
14 Jul 2025	Form 4: Boyd Matthew Ross, Chief Regulatory Officer Granted 100,000 Stock Option (Right to Buy)
10 Jul 2025	Form 4: Astley-Sparke Philip, Director Granted 45,000 Stock Option (Right to Buy)

Comments